Open AccessThe role of Lyn kinase in the development of imatinib resistance in chronic myelogenous leukemia
Author(s) -
Camillo Porta,
Federica Tagliani
Publication year - 2011
Publication title -
oncology reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.637
H-Index - 21
eISSN - 1970-5565
pISSN - 1970-5557
DOI - 10.4081/oncol.2008.111
Subject(s) - medicine , chronic myelogenous leukemia , imatinib , lyn , imatinib mesylate , nilotinib , tyrosine kinase , pharmacology , tyrosine kinase inhibitor , tolerability , leukemia , abl , cancer research , receptor , myeloid leukemia , adverse effect , cancer
Imatinib mesylate, a small-molecule inhibitor of BCRABL tyrosine kinase activity, has emerged as the well-recognized standard of treatment for chronic myelogenous leukemia (CML). Indeed, both its efficacy, tolerability, as well as cost-effectiveness have been clearly proven...
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom